UroGen Pharma Ltd.

LSE:0XOD Stock Report

Market Cap: US$526.6m

UroGen Pharma Management

Management criteria checks 2/4

UroGen Pharma's CEO is Liz Barrett, appointed in Jan 2019, has a tenure of 5.83 years. total yearly compensation is $4.64M, comprised of 17.1% salary and 82.9% bonuses, including company stock and options. directly owns 0.77% of the company’s shares, worth $4.08M. The average tenure of the management team and the board of directors is 4.3 years and 5.8 years respectively.

Key information

Liz Barrett

Chief executive officer

US$4.6m

Total compensation

CEO salary percentage17.1%
CEO tenure5.8yrs
CEO ownership0.8%
Management average tenure4.3yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Liz Barrett's remuneration changed compared to UroGen Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$115m

Jun 30 2024n/an/a

-US$114m

Mar 31 2024n/an/a

-US$104m

Dec 31 2023US$5mUS$794k

-US$102m

Sep 30 2023n/an/a

-US$105m

Jun 30 2023n/an/a

-US$109m

Mar 31 2023n/an/a

-US$112m

Dec 31 2022US$2mUS$764k

-US$110m

Sep 30 2022n/an/a

-US$109m

Jun 30 2022n/an/a

-US$114m

Mar 31 2022n/an/a

-US$113m

Dec 31 2021US$4mUS$739k

-US$111m

Sep 30 2021n/an/a

-US$113m

Jun 30 2021n/an/a

-US$111m

Mar 31 2021n/an/a

-US$117m

Dec 31 2020US$2mUS$637k

-US$128m

Sep 30 2020n/an/a

-US$137m

Jun 30 2020n/an/a

-US$130m

Mar 31 2020n/an/a

-US$121m

Dec 31 2019US$26mUS$695k

-US$105m

Compensation vs Market: Liz's total compensation ($USD4.64M) is above average for companies of similar size in the UK market ($USD989.04K).

Compensation vs Earnings: Liz's compensation has increased whilst the company is unprofitable.

CEO

Liz Barrett (62 yo)

5.8yrs

Tenure

US$4,639,589

Compensation

Ms. Elizabeth A. Barrett, also known as Liz, has been President, Chief Executive Officer and Director of UroGen Pharma Ltd. since January 3, 2019. She has been a Director at Allogene Therapeutics, Inc. sin...

Leadership Team

NamePositionTenureCompensationOwnership
Elizabeth Barrett
President5.8yrsUS$4.64m0.77%
$ 4.1m
Jason Smith
General Counsel4.3yrsUS$1.51m0.060%
$ 314.8k
Mark Schoenberg
Chief Medical Officer6.9yrsUS$1.36m0.34%
$ 1.8m
Christopher Degnan
Chief Financial Officerless than a yearno datano data
Vincent Perrone
Senior Director of Investor Relationsno datano datano data
Bryon Wornson
Executive Vice President of Talent1.3yrsno datano data
Marina Konorty
Executive Vice President of Research & Development and Technical Operations4.7yrsno datano data
James Ottinger
Executive Vice President of Regulatory Affairs & Quality4.7yrsno datano data
Polly Murphy
Chief Business Officer4.2yrsno datano data
Michael Louie
Senior Vice President of Medical Affairs & Clinical Development1.3yrsno datano data
David Lin
Chief Commercial Officerless than a yearno datano data
Gil Hakim
Consultant6.3yrsUS$3.86mno data

4.3yrs

Average Tenure

56.5yo

Average Age

Experienced Management: 0XOD's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Elizabeth Barrett
President5.8yrsUS$4.64m0.77%
$ 4.1m
Cynthia Butitta
Independent Director7.1yrsUS$204.06k0%
$ 0
Stuart Holden
Independent Director8.9yrsUS$201.53k0%
$ 0
Arie Belldegrun
Independent Chairman11.9yrsUS$342.18k0.97%
$ 5.1m
Daniel Wildman
Independent Director2yrsUS$192.72k0%
$ 0
Jack Baniel
Member of Scientific Advisory Boardno datano datano data
Herbert Lepor
Chairman of Scientific Advisory Boardno datano datano data
Fred Witjes
Member of Scientific Advisory Boardno datano datano data
James Robinson
Independent Director1.3yrsUS$313.29k0%
$ 0
Leana Wen
Independent Director2.3yrsUS$194.41k0%
$ 0

5.8yrs

Average Tenure

67yo

Average Age

Experienced Board: 0XOD's board of directors are considered experienced (5.8 years average tenure).